Intracellular delivery of proapoptotic peptide drugs for the treatment of cancer

用于治疗癌症的促凋亡肽药物的细胞内递送

• 批准号: 8302741
• 负责人: Patrick S. Stayton
• 金额: $ 25.62万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-09 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8302741
• 关键词: Abnormal Cell; Address; Advanced Malignant Neoplasm; Adverse effects; Animals; Antibodies; Antineoplastic Agents; Apoptosis; Apoptotic; Binding; Biodistribution; Bioluminescence; Biomimetics; Biotin; Blood Circulation; Cancer Model; Cancerous; Caspase; Cause of Death; Cell Death; Cells; Cessation of life; Cisplatin; Clinical; Collaborations; Cytoplasm; Data; Development; Disulfide Linkage; Drug Delivery Systems; Drug Design; Drug Formulations; Effectiveness; Electron Microscopy; Family; Fred Hutchinson Cancer Research Center; Future; Gene Proteins; Growth; Human; Image; Intracellular Membranes; Lead; Luciferases; Malignant Epithelial Cell; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Measurement; Micelles; Molecular Sieve Chromatography; Molecular Weight; Monitor; NMR Spectroscopy; Operative Surgical Procedures; Ovarian Carcinoma; Paclitaxel; Pathway Analysis; Pathway interactions; Patients; Peptide antibodies; Peptides; Pharmaceutical Preparations; Phase; Polymers; Property; Proteins; Radiation; Recurrence; Research Personnel; Research Proposals; Resistance; Roche brand of trastuzumab; Scintillation Counting; Screening procedure; Signal Transduction; Small Interfering RNA; Subgroup; System; Technology; Therapeutic; Tissues; Toxic effect; Treatment Efficacy; United States; Validation; Xenograft Model; base; cancer cell; cancer therapy; chemotherapy; clinical application; clinically relevant; design; di-block copolymer; experience; fluorophore; improved; in vivo; indexing; intraperitoneal; light scattering; member; mitochondrial membrane; mouse model; neoplastic cell; novel therapeutics; ovarian neoplasm; polymerization; small molecule; tumor; tumor growth; zeta potential

DESCRIPTION (provided by applicant): Many cancers are thought to be caused by survival and growth of abnormal cells with impaired apoptotic machinery that, under normal circumstances, would undergo programmed cell death. Short peptides containing pro-apoptotic subgroups that antagonize the anti-apoptotic members have been developed as a means of restoring normal apoptotic signaling. However, cell specific peptide-based drugs that trigger apoptosis in cancerous cells while avoiding toxicity to healthy tissues have not yet achieved clinical utility. Despite the enthusiasm for peptide-based therapeutics, formidable obstacles persist that hinder their clinical application in humans with advanced cancer. Maintaining peptide stability and bioactivity as well as achieving targeted, intracellular delivery remain as major hurdles that must be overcome before these and other therapeutic peptides can be applied to in vivo systems and thereby realize their full potential. This proposal will bring together the Stayton Lab's drug delivery systems with the Press' labs clinical cancer experience to develop preliminary animal validation of functional proapoptotic peptide delivery in an ovarian cancer model. The unifying hypothesis underlying this research proposal is that facilitating tumor targeting, circulation stability, and translocation of proapoptotic peptides across intracellular membranes will augment their anti- tumor potency and substantially enhance their effectiveness. In addition, the project will evaluate the potential of antibody targeting in a xenograft model to enhance tumor localization using a herceptin-targeted carrier system. This project will take advantage of a strong cross-institutional collaboration between the Stayton group at UW and the Press group at the FHCRC to build strong preliminary data to support a future multi-investigator proposal around new peptide-based therapies for ovarian cancer. PUBLIC HEALTH RELEVANCE: Cancer remains a leading cause of death in the United States. Radiation and chemotherapy lead to negative side effects caused by toxicity in healthy tissues and are prone to tumor persistence and recurrence due to emergence of resistant cells. In order to address this unmet need this proposal will design and synthesize targeted polymeric carrier that can be utilized to deliver pro-apoptotic peptides to enhance tumor cell death in vivo.

描述（由申请人提供）：许多癌症被认为是由凋亡机制受损的异常细胞的存活和生长引起的，在正常情况下，这些细胞会经历程序性细胞死亡。含有促凋亡亚群的短肽可拮抗抗凋亡成员，已被开发为恢复正常凋亡信号的一种手段。然而，基于细胞特异性肽的药物在触发癌细胞凋亡的同时避免对健康组织的毒性，尚未实现临床应用。尽管人们对基于肽的治疗方法充满热情，但阻碍其在晚期癌症患者中的临床应用的巨大障碍仍然存在。维持肽的稳定性和生物活性以及实现靶向，细胞内递送仍然是必须克服的主要障碍，才能将这些和其他治疗性肽应用于体内系统，从而充分发挥其潜力。该提案将把Stayton实验室的药物输送系统与Press实验室的临床癌症经验结合起来，在卵巢癌模型中开发功能性促凋亡肽输送的初步动物验证。本研究建议的统一假设是促进肿瘤靶向，循环稳定性和促凋亡肽跨细胞膜的易位将增强其抗肿瘤效力并大大提高其有效性。此外，该项目将评估抗体靶向在异种移植模型中的潜力，以使用赫赛汀靶向载体系统增强肿瘤定位。该项目将利用华盛顿大学的Stayton小组和FHCRC的Press小组之间强有力的跨机构合作，建立强有力的初步数据，以支持未来围绕新的基于肽的卵巢癌治疗方法的多研究者提案。